Literature DB >> 6972784

Characteristics of an aminohydrolase distinct from adenosine deaminase in cultured human lymphoblasts.

P E Daddona, W N Kelley.   

Abstract

An inherited deficiency of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) is associated with an autosomal recessive form of severe combined immunodeficiency disease. Affected patients exhibit markedly reduced or absent adenosine deaminating activity in various tissues. In this study we have demonstrated the presence of a low level aminohydrolase activity in 11 different normal and adenosine deaminase-deficient lymphoblast cell lines which is apparently distinct from normal adenosine deaminase. Based on enzymatic, physical and immunoreactive properties, this lymphoblast aminohydrolase does not appear to be related to adenosine deaminase and is most likely coded for by a different gene locus. In future investigations designed to characterize mutant forms of adenosine deaminase, it will be important to distinguish this lymphoblast aminohydrolase activity from putative products of the adenosine deaminase gene locus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972784     DOI: 10.1016/0005-2744(81)90298-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity.

Authors:  Andrey V Zavialov; Ake Engström
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

2.  Demonstration of adenosine deaminase activity in human fibroblast lysosomes.

Authors:  E R Lindley; R L Pisoni
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

3.  Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

Authors:  P E Daddona; B S Mitchell; H J Meuwissen; B L Davidson; J M Wilson; C A Koller
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

4.  Partial adenosine deaminase deficiency: another family from southern Africa.

Authors:  S L Hart; A B Lane; T Jenkins
Journal:  Hum Genet       Date:  1986-11       Impact factor: 4.132

5.  Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.

Authors:  R Hirschhorn; D R Yang; A Israni; M L Huie; D R Ownby
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

6.  Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.

Authors:  D Valerio; M G Duyvesteyn; H van Ormondt; P Meera Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

7.  Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer.

Authors:  P W Kantoff; D B Kohn; H Mitsuya; D Armentano; M Sieberg; J A Zwiebel; M A Eglitis; J R McLachlin; D A Wiginton; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.

Authors:  F X Arredondo-Vega; J Kurtzberg; S Chaffee; I Santisteban; E Reisner; M S Povey; M S Hershfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

9.  Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p.

Authors:  Yara A Samra; Heba M Saleh; Khaled A Hussein; Nehal M Elsherbiny; Ahmed S Ibrahim; Khaled Elmasry; Sadanand Fulzele; Mamdouh M El-Shishtawy; Laila A Eissa; Mohamed Al-Shabrawey; Gregory I Liou
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-02-01       Impact factor: 4.799

10.  Adenosine deaminase 2 activity negatively correlates with age during childhood.

Authors:  Sarah M Bowers; Kristen M Gibson; David A Cabral; Kelly L Brown
Journal:  Pediatr Rheumatol Online J       Date:  2020-07-10       Impact factor: 3.054

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.